Skip to main content
    A

    Alaunos Therapeutics Inc (TCRT)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $1.66
    +0.06 (+3.75%)

    Market Cap: $6.86M

    Last updated: Nov 17, 2026 at 4:15 PM ET

    Alaunos Therapeutics Inc (TCRT) Statistics

    Updated Nov 17, 2026. Figures from company filings and market prices; estimates from consensus analysts.

    Alaunos Therapeutics (TCRT) has a market cap of $6.86M and an enterprise value of $6.24M. It kept -120766.67% of revenue as net income over the last 12 months. Its share count is up 19.31% from a year earlier.

    Total Valuation

    Enterprise value is 8.97% below the market cap, as cash exceeds debt.

    Market Cap$6.86M
    Enterprise Value$6.24M
    Latest price (Nov 17, 2026)$1.66

    Key Dates

    The next earnings report is expected on Mar 29, 2027, covering the quarter ending Dec 31, 2026.

    Next Earnings DateMar 29, 2027 (expected)
    Last Earnings DateAug 14, 2026
    Fiscal Year EndDecember

    Share Statistics

    The share count rose 7.11% in the quarter ended Sep 30, 2026 and grew 27.54% a year over 2 years.

    Shares Outstanding2.60M
    Shares Change (YoY)+19.31%
    Shares Change (QoQ)+7.11%
    Share Count Growth (2Y CAGR)+27.54%

    Price Statistics

    The stock is down 44.11% over 52 weeks and trades 1.22% above its 50-day average.

    Beta (1Y)0.94
    52-Week Change-44.11%
    1-Month Change-46.96%
    3-Month Change-11.70%
    6-Month Change-33.60%
    5-Year Change-99.13%
    10-Year Change-99.77%
    Total Return (1Y)-44.11%
    Total Return (3Y CAGR)-45.23%
    Total Return (5Y CAGR)-62.10%
    Return vs SPY (1Y)-61.86%
    Max Drawdown (1Y)-82.97%
    Max Drawdown (3Y)-97.33%
    Sharpe Ratio (1Y)-0.48
    Correlation with SPY (1Y)0.09
    50-Day Average$1.64
    200-Day Average$2.26
    52-Week Range$0.72 to $4.50
    RSI (14 Days)46.1
    Average Volume (20 Days)497.68K

    The 5 and 10 year changes compare month-end closes, adjusted for splits, through Oct 2026.

    Price chart

    Financial Position

    Current assets cover 1.14x current liabilities, and total debt is 0.00x shareholder equity.

    Current Ratio1.14x
    Quick Ratio1.14x
    Debt / Equity0.00x

    Returns and Efficiency

    Return on equity is -373.12% and return on assets is -188.89% over the last 12 months.

    Return on Equity (ROE)-373.12%
    Return on Assets (ROA)-188.89%
    Return on Capital Employed (ROCE)-369.93%
    Asset Turnover0.00x

    Scores

    TCRT has an Altman Z-Score of -680.26, in the distress zone below 1.81, and a Piotroski F-Score of 2 of 9, in the weak band of 0 to 2.

    Altman Z-Score-680.26
    Altman Z ZoneDistress
    Piotroski F-Score2 of 9
    Piotroski StrengthWeak

    Income Statement

    Revenue of $3.00K over the last 12 months is down 57.14% from the 12 months before.

    Revenue$3.00K
    Revenue Growth (YoY)-57.14%
    Gross Profit$3.00K
    Operating Income-$3.63M
    Pretax Income-$3.59M
    Net Income-$3.62M
    EBITDA-$3.56M
    EBIT-$3.59M

    Trailing 12 months through Sep 30, 2026.

    Full financial statements

    Balance Sheet

    Shareholder equity funds 50.57% of the $1.92M in total assets.

    Cash and Equivalents$615.00K
    Total Debt$0
    Net Cash$615.00K
    Net Cash Per Share$0.24
    Working Capital$129.00K
    Shareholder Equity$971.00K
    Book Value Per Share$0.37
    Total Assets$1.92M
    Total Liabilities$947.00K

    Balance sheet as of Sep 30, 2026.

    Full balance sheet

    Cash Flow

    Operating Cash Flow-$2.31M
    FCF Per Share-$0.55
    Depreciation and Amortization$32.00K

    Trailing 12 months through Sep 30, 2026.

    Full cash flow statement

    Margins

    The operating margin is -121033.33%.

    Gross Margin100.00%
    Operating Margin-121033.33%
    Pretax Margin-119733.33%
    Net Margin-120766.67%
    EBITDA Margin-118666.67%
    EBIT Margin-119733.33%

    Growth

    Revenue fell 88.04% a year over 3 years.

    Revenue Growth (3Y CAGR)-88.04%
    Book Value Per Share Growth (2Y CAGR)-47.03%
    Tangible Book Per Share Growth (2Y CAGR)-47.03%

    Revenue and profit by year

    Dividends and Yields

    TCRT does not pay a dividend.

    Buyback Yield-21.19%
    Shareholder Yield-21.19%

    Stock Splits

    The last split was a 1-for-10 reverse split on Jul 18, 2024.

    Last Split DateJul 18, 2024
    Split TypeReverse split
    Split Ratio1:10

    Price Target

    Analyst price targets are part of paid GNG plans. See plans

    Frequently Asked Questions About TCRT

    What is TCRT's market cap?

    Alaunos Therapeutics has a market cap of $6.86M. Its enterprise value, which adds debt and subtracts cash, is $6.24M.

    How many shares of TCRT are outstanding?

    Alaunos Therapeutics has 2.60M shares outstanding. The count is up 19.31% from a year earlier.

    Does TCRT pay a dividend?

    No. Alaunos Therapeutics does not pay a dividend.

    How much debt does TCRT have?

    Alaunos Therapeutics has $0 of total debt and $615.00K of cash and equivalents, a net cash position of $615.00K.